SEC Form 4 · accession 0001179110-18-002464
Syros Pharmaceuticals, Inc. · SYRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Eric R Olson
Officer — Chief Scientific Officer
Period of report
Feb 16, 2018
Accepted (ET)
Feb 21, 2018 · 4:08 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001556263
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $10.09 | Feb 16, 2018 | A | 75,000 | A | — | Feb 15, 2028 | Common Stock | 75,000 | 75,000 | D |
Explanation of responses
- F1This option becomes exercisable as to 25% of the shares underlying the award on February 28, 2019, with the remainder vesting in equal monthly installments of 2.0833% of the shares underlying the award at the end of each successive month thereafter.